Equity Incentives from Travere Therapeutics
Travere Therapeutics, Inc. (NASDAQ: TVTX), based in San Diego, has recently made headlines with its announcement regarding inducement equity grants. This initiative highlights the company’s commitment to attracting talent within the biopharmaceutical sector, particularly as it addresses the critical challenges faced by patients with rare diseases.
Details of the Inducement Grants
On a recent date, the Compensation Committee of Travere’s Board of Directors granted a strategic inducement program that includes equity grants to six new employees. This initiative encompasses inducement restricted stock units (RSUs) totaling 24,400 shares of common stock. The RSUs are structured under Travere's 2018 Equity Incentive Plan, even though they were granted outside the standard plan provisions, aligning with the Nasdaq Listing Rule 5635(c)(4).
Vesting of Stock Units
The newly issued RSUs are set to vest over a four-year period. Each year, 25% of the granted shares become available on the anniversary of the initial grant date, subject to the continuous employment of these employees with Travere. This vesting schedule reflects a long-term commitment to the workforce and underlines the importance of stability in the continuity of their mission.
About Travere Therapeutics
Travere Therapeutics is dedicated to addressing rare diseases and improving the lives of patients and their families. This biopharmaceutical company operates on the principle that every individual with a rare disease deserves access to treatment options and support. Travere’s global team works tirelessly to engage with the rare disease community, aiming to develop therapies that can significantly change the course of these conditions. Each initiative reflects their dedication to understanding the unique challenges faced by these patients.
Community Engagement and Impact
In its commitment to fostering hope and resilience, Travere actively collaborates with patients, families, and caregivers to gather insights that drive research and development. The company recognizes the urgency of need for effective treatment options and aims to cultivate a deeper understanding of the diverse perspectives within the rare disease landscape.
Contact Information
For further inquiries, interested parties can reach out through the following channels:
Media Inquiries
For media related concerns, you can contact Travere at 888-969-7879 or via email at mediarelations@travere.com.
Investor Relations
Investors can also connect with the company through the same phone number, 888-969-7879, or by emailing IR@travere.com.
Frequently Asked Questions
What are the main features of the inducement grants announced by Travere?
The inducement grants consist of restricted stock units (RSUs) totaling 24,400 shares, designed to attract six new employees to the company.
How long is the vesting period for the RSUs?
The RSUs vest over four years, with 25% vesting on each anniversary of the grant date, contingent on the employee's continued service.
What is the mission of Travere Therapeutics?
Travere Therapeutics aims to help patients with rare diseases by developing life-changing therapies while engaging with the patient community.
How does Travere engage with the rare disease community?
The company collaborates with patients and caregivers to understand their needs, drive research, and deliver impactful treatment options.
Who can be contacted for media or investor inquiries?
For media inquiries, contact 888-969-7879 or email mediarelations@travere.com. For investor relations, use the same number or email IR@travere.com.
